Anti‐RGMa monoclonal antibody (anti‐RGMa) has been shown to reduce disease severity and promote neurological recovery in multiple disease animal models, including neuromyelitis optica[20] and spinal cord injury.[21] It should be noted that RGMa has been reported to promote resolution and tissue repair in a murine acute peritonitis model.[22, 23] To avoid potential side effects and enhance therapeutic efficacy, it would be best to target anti‐RGMa to the ischemic region. The gene discussed is RGMA; the disease is neuromyelitis optica.